Hodgkin's disease: A disorder of dysregulated cellular cross-talk

Biotherapy

Volumn 10, Issue 4, 1998, Pages 309-320

  Pinto, Antonio ^a   Gattei, Valter ^a   Zagonel, Vittorina ^a   Aldinucci, Donatella ^b   Degan, Massimo ^a   De Iuliis, Angela ^a   Rossi, Francesca Maria ^a   Mazzocco, Francesca Tassan ^a   Godeas, Cristiana ^b   Rupolo, Maurizio ^a   Poletto, Dalisa ^a   Gloghini, Annunziata ^a   Carbone, Antonino ^b   Gruss, Hans Jürgen ^b  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Cell contact dependent interactions; Cytokine network; Hodgkin's disease; Human lymphomas

Indexed keywords

LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; NERVE GROWTH FACTOR; STEM CELL FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

ARTICLE; CELL CONTACT; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REED STERNBERG CELL; T CELL LEUKEMIA; TUMOR CELL CULTURE;

EID: 0031897030     PISSN: 0921299X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02678551     Document Type: Article

References (106)

1. HarrisNL,JaffeES,SteinH,BanksPM,ChanJK,ClearyML, Delsol G, De Wolf Peelers C, Falini B, Gatter KC. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study group. Blood 1994; 84:1361-1392.
2. Kaplan HS. Hodgkin's Disease. 2nd ed. Cambridge, MA: Harvard University Press, 1980.
3. Banks PM. The pathology of Hodgkin's disease. Semin Oncol 1990; 17: 683-689.
4. Butler JJ. The histologie diagnosis of Hodgkin's disease. Sem Diagn Pathol 1992; 9: 252-256.
5. Kadin ME. Pathology of Hodgkin's disease. Cure Opinion Oncol 1994; 6: 456-463.
6. Carbone A, Manconi R, Poletti A, Sulfaro S, Menin A, Tirelli U, Betta PG, Volpe R. Reed-Sternberg cells and their cell microenvironment in Hodgkin's disease with reference to macrophage-histiocytes and interdigitating reticulum cells. Cancer 1987; 60: 2662-6268.
7. Wright DH. Out of the Hodgkin's maze? J Pathol 1995; 177: 331-333.
8. Haluska FG, Brufsky AM, Cannellos GP. The cellular biology of Reed-Steraberg cell. Blood 1995; 84: 1005-1019.
9. Delabie J, Tierens A, Wu G, Weisenburger DD, Chan WC. Lymphocyte predominance Hodgkin's disease: lineage and clonality determination using a single-cell assay. Blood 1994; 84:3291-3298.
10. Mason D., Banks PM, Chan J, Cleary ML, Delsol G, de Wolf Peelers C, Falini B, Gatter K, Grogan TM, Harris NL. Nodular lymphocyte predominance Hodgkin's disease. A distincl clinicopathological entity. Am J Surg Pathol 1994; 18: 526530.
11. Poppema S. The nature of the lymphocytes surrounding Reed-Sternberg cells in nodular lymphocyte predominance and in other types of Hodgkin's disease. Am J Pathol 1989; 135: 351-357.
12. Poppema S, De Jong B, Atmosoerodjo J, Idenburg V, Visser L, De Ley L. Morphologic, immunologie, enzymehistochemical and chromosomal analysis of a cell line derived from Hodgkin's disease. Evidence foraB-cell origin of SternbergReed cells. Cancer 1985; 55: 683-690.
13. Poppema, S. The biology of Hodgkin's disease. Ann Oncol 1992; 3 (Suppl. 4): 5-8.
14. Schmid C, Pan L, Diss T, Isaacson PG. Expression of B-cell antigens by Hodgkin's disease and Reed-Sternberg cells. Am J Pathol 1991; 139:701-707.
15. Isaacson PC, Ashton Key M. Phenotype of Hodgkin and Reed-Sternberg cells. Lancet 1996; 347:481.
16. Carbone A, Gloghini A, Gattei V, Degan M, Improta S, Aldinucci D, Canzonieri V, Perm T, Volpe R, Gaidano G, Zagonel V, Pinto A. Reed-Sternberg cells of classical Hodgkin's disease react with the plasma cell-specific monoclonal antibody B-B4 and express human syndecan-1. Blood 1997; 89:3787-3794.
17. Kadin ME, Muramoto L, Said J. Expression of T-cell antigens on Reed-Sternberg cells in a subset of patients with nodular sclerosing and mixed cellularity Hodgkin's disease. Am 3 Pathol 1988; 130: 345-353.
18. Dallenbach FE, Stein H. Expression of T-cell receptor beta chain in Reed-Sternberg cells. Lancet 1989; ii: 828-830.
19. Drexler, HG. Recent results on the biology of Hodgkin and Reed-Sternberg cells. I. Biopsy material. Leuk Lymph 1992; 8: 283-303.
20. Inghirami G, Macri, L, Rosati S, Zhu BY, Yee HT, Knowles DM. The Reed-Sternberg cells of Hodgkin disease are clonal Proc Natl Acad Sei USA 1994; 91: 9842-9846.
21. Tamara J-i, Hummel M, Zemlin M, Kalvelage B, Stein H. Hodgkin's disease with B-cell phenotype oftes shows a VDJ rearrangement and somatic mutations in the VH genes. Blood 1994; 84: 708-715.
22. Hummel M, Ziemann K, Lammert H, Pileri S, Sabattini E, Stein H. Hodgkin's disease with monoclonal and polyclonal populations of Reed-Sternberg cells. N. Engl J Med 1995; 333: 901-906.
23. Hummel M, Marafioti T, Stein H. Immunoglobulin V genes in Reed-Sternberg cells. N Engl J Med 1996; 334:405-406.
24. Küppers M, Loftin U, von Bonin F, von Bonin F, Cause A, Pfreundschuh M, Daus H, Tramper L. (1996a) Single cell PCR for the analysis of Hodgkin's disease: four years later. Ann Oncol 1996; 7 (Suppl 4): 35-39.
25. Delabie J, Tierens A, Gavriil T, Wu G, Weisenburger DD, Chan WC Phenotype, genotype and clonatity of ReedSternberg cells in nodular sclerosis Hodgkin's disease: results of a single-cell study. Br J Haematol 1996; 94: 198-205.
26. Küppers R, Rajewsky K, Zhao M, Simons G, Laumann R, Fischer R, Hansmann ML. Hodgkin's disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sei USA 1994; 91:10962-10966.
27. Kanzler H, Küppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 1996; 184: 1495-1505.
28. Kanzler H, Hansmann ML, Kapp U, Wolf J, Diehl V, Rajewsky K, Küppers R. Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line (L1236) from the Hodgkin/Reed-Sternberg cells of a Hodgkin's lymphoma patient. Blood 1996; 87: 3429-3436.
29. Küppers R, Kanzler H, Hansmann ML, Rajewsky K. Single cell analysis of Hodgkin/Reed-Stemberg cells. Ann Oncol 1996; 7 (Suppl 4): 27-30.
30. Küppers R, Kanzler H, Hansmann ML, Rajewsky K. Immunoglobulin V genes in Reed-Sternberg cells. N Engl J Med 1996; 334: 404.
31. Rajewsky K, Kanzler H, Hansmann ML, Küppers R. Normal and malignant B-cell development with special reference to Hodgkin's disease. Ann Oncol 1997; 8 (Suppl. 2): 79-81.
32. Daus H, Trumper L, Roth J, von Bonin F, Moller P, Cause A, Pfreundschuh M. Hodgkin and Reed-Sternberg cells do not carry T-cell receptor gamma gene rearrangements: Evidence from single-cell polymerase chain reaction examination. Blood 1995; 85: 1590-1595.
33. Pinkus OS, Said JW. Hodgkin's disease, lymphocyte predominance type, nodular-further evidence for a B-cell derivation. L&H variants of Reed-Sternberg cells express L26, a pan B cell marker. Am J Pathol 1988; 133: 211-217.
34. Poppema S. Lymphocyte predominance Hodgkin's disease. Sem Diagn Pathol 1992; 9: 257-264.
35. Grass HJ, Pinto A, Duyster J, Poppema S, Herrmann F. Hodgkin's disease: a tumor with disturbed immunological pathways. Immunol Today 1997; 18:156-163.
36. Dürkop H, Latza U, Hummel M, Eithelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992; 68: 421-427.
37. Smith CA, Grass HJ, Davis T, Anderson D, Andersen D, Farrah T, Baker E, Sutherland GR, Brannan CI, Copeland NO, Jenkins NA, Grabstein KH, Gliniak B, McAlister IB, Fanslow W, Alderson M, Falk B, Gimpel S, Gillis S, Din SW, Goodwin RG, Armitage RJ. CD30 antigen, a marker for Hodgkin's lymphoma is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993; 73: 1349-60.
38. Grass HJ, Hirschstein D, Wright B, Ulrich D, Caligiuri MA, Strockbine L, Armitage RJ, Dower SK. Expression and function of CD40 on Hodgkin and Reed-Stemberg cells and the possible relevance for Hodgkin's disease. Blood 1994; 84: 2305-2314.
39. O'Grady JT, Stewart S, Lowrey J, Howie SE, Krajewski AS. CD40 expression in Hodgkin's disease. Am J Pathol 1994; 144: 21-26.
40. Carbone A, Gloghini A, Gattei V, Aldinucci D, Degan M, De Paoli P, Zagonel V, Pinto A. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood 1995; 85: 780-789.
41. Falini B, Pileri S, Pizzolo G, Durkop H, Flenghi L, Stirpe F, Martelli MF, Stein H. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995; 85:1-14.
42. Bancherau J, Bazan F, Briere F, Galizzi JP, van Kooten C, Liu YJ, Roussel F, Sealand S. The CD40 antigen and its ligand. Annu Rev Immunol 1994; 12: 881-922.
43. Smith GA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994; 76: 959-962.
44. Gruss HJ, Dower SK. TNF ligand superfamily: involvement in the pathology of malignant lymphomas. Blood 1995; 85: 3378-3344.
45. Gruss HJ, Dower SK. The TNF ligand superfamily and its relevance for human diseases. Cytok Mol Ther 1995; 1: 7576.
46. Armitage RJ. Tumor necrosis factor receptor superfamily members and their ligands. Curr Opin Immunol 1994; 6: 407-113.
47. Grass HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 1994; 83: 2045-2056.
48. Carbone A, Gloghini A, Gruss HJ, Pinto A. CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease. Am J Pathol 1995; 147: 912-922.
49. Gruss HJ, Pinto A, Gloghini A, Wright B, Boiani N, Aldinucci D, Gattei V, Zagonel V, Smith GA, Kadin ME, von Schilling C, Goodwin RG, Herrmann F, Carbone A. CD30 ligand expression in normal, reactive and Hodgkin's diseaseinvolved lymph nodes. Am J Pathol 1996; 149: 469-481.
50. Grass HJ, Duyster J, Herrmann F. Structural and biological features of the TNF receptor and TNF ligand superfamilies: interactive signals in the pathobiology of Hodgkin's disease. Ann Oncol 1996; 7(Suppl. 4): 19-26.
51. Pinto A, Aldinucci D, Gloghini A, Zagonel V, Degan M, Improta S, Juzbasic S, Todesco M, Perin V, Gattei V, Herrmann F, Gruss HJ, Carbone A. Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. Blood 1996; 88: 3299-3305.
52. Pinto A, Aldinucci D, Gloghini A, Zagonel V, Degan M, Perin V, Todesco M, De lulus A, Improta S, Sacco C, Gattei V, Gruss HJ, Carbone A. The role of eosinophils in the pathobiology of Hodgkin's disease. Ann Oncol 1997; 8 (Suppl. 2): 89-96.
53. Gattei V, Degan M, Gloghini A, De Iuliis A, Improta S, Rossi FM, Aldinucci D, Perin V, Serraino D, Babare R, Zagonel V, Gruss HJ, Carbone A, Pinto A. CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin. Blood 1997; 89: 2048-2059.
54. Pinkus GS, Thomas P, Said JW. Leu-Mi - a marker for ReedSternberg cells in Hodgkin's disease. An immunoperoxidase study of paraffin-embedded tissues. Am J Pathol 1985; 119: 244-252.
55. Chittal SM, Caverivière P, Schwarting R, Gerdes J, Al Saati T, Rigal-Huguet F, Stein H, Delsol G. Monoclonal antibodies in the diagnosis of Hodgkin's disease: the search for a rational panel. Am J Surg Pathol 1988; 12: 9-13.
56. Bilbe G, Delabie J, Bruggen J, Richener H, Asselbergs FA, Cerletti N, Sorg C, Odink K, Tarcsay L, Wiesendanger W. Restin: A novel intermediate filament-associated protein highly expressed in the Reed-Sternberg cells of Hodgkin's disease. EMBO J 1992; 11: 2103-2113.
57. Delabie J, Shipman R, Bruggen J, De Strooper B, van Leuven F, Tarcsay L, Cerletti N, Odink K, Diehl V, Bilbe G. Expression of the novel intermediate filament-associated protein restin in Hodgkin's disease and anaplastic large-cell lymphoma. Blood 1992; 80: 2891-2896.
58. Baker SJ, Reddy EP. Transducers of life and death: TNF receptor superfamily and associated proteins. Oncogene 1996; 12: 1-12.
59. Gruss HJ, Hermann F, Drexler HG. Hodgkin's disease: a cytokine producing tumor. Crit Rev Oncog 1994; 5: 23-88.
60. Grass HJ, Ulrich D, Braddy S, Armitage RJ, Dower SK. Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells. EUT J Immunol 1995; 25: 2083-2089.
61. Yang YC. Human lnterleukin-9: a new cytokine in hematopoiesis. Leuk Lymph 1992; 8: 441-447.
62. Engelmann H, Novick D, Wallach D. Two tumor necrosis factor binding protein purified from human urine. Evidence for immunological cross reactivity with cell surface tumor necrosis factor receptors. JBiolChem 1990; 265:1531-1536.
63. Hintzen RQ, de Jong R, Hack CE, Chamuleau M, de Vries EFR, Ten Berge IJM, Borst J, van Lier RAW. A soluble form of the human T cell differentiation antigen CD27 is released after triggering of the TCR/CD3 complex. J Immunol 1991; 147: 29-35.
64. Josimovic-Alasevic O, Dürkop H, Schwarting R, Backe E, Stein H, Diamantstein T. Ki-1 (CD30) antigen is released by Ki-1 -positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatant and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol 1989; 19: 157-162.
65. Ellis TM, Simms PE, Slivink DJ, Jack HM, Fisher RI. CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J Immunol 1993; 151: 23802423.
66. Pizzolo G, Vinante F, Morosato L, Nadali G, Chilosi M, Gandini G, Sinicco A, Raiteri R, Semenzato G, Stein H. High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS. AIDS 1994; 8: 741-746.
67. Del Prête GF, Maggi E, Pizzolo G, Romagnani S. CD30, Th2 cytokines and HIV infection: a complex and fascinating link. Immunol Today 1995; 16:76-80.
68. Cause A, Pohl C, Tscheirsch A, Da Costa L, Jung W, Diehl V, Hasenclever D, Pfreundschuh M. Clinical significance of soluble CD30 antigen in the sera of patients with with untreated Hodgkin's disease. Blood 1991; 77: 1983-1988.
69. Nadali G, Vinante F, Ambrosetti A, Todeschini G, Venen D, Zanotti R, Meneghini V, Ricetti MM, Benedetti F, Vassanelli A, Perona G, Chilosi M, Menestrina F, Fiacchini M, Stein H, Pizzolo G. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. J Clin Oncol 1994; 12:793-779.
70. Grass HJ, Dölken G, Brach MA, Mertelsmann R, Hermann F. Serum levels of circulating ICAM-1 are increased in Hodgkin's disease. Leukemia 1993; 7: 1245-1249.
71. Grass HJ, Dölken G, Brach MA, Mertelsmann R, Herrmann F. The significance of serum levels of soluble 60kDa receptors for tumor necrosis factor in patients with Hodgkin's disease. Leukemia 1993; 7: 1339-1343.
72. Gause A, Jung W, Keymis S, Schobert I, Scholz R, Schmits R, Diehl V, Pohl C, Hasenclever D, Pfreundschuh M. The clinical significance of cytokines and soluble forms of membranederived activation antigens in the serum of patients with Hodgkin's disease. Leuk Lymph 1992; 7:439-447.
73. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263: 1759-1762.
74. Merz H, Fliedner A, Orscheschek K, Binder Th, Sebald W, Muller-Hermelink HK, Feller AC. Cytokine expression in Tcell lymphomas and Hodgkin's disease. Am J Pathol 1991; 139: 1173-1180.
75. Gruss HJ, Brach MA, Drexler HG, Bross KJ, Herrmann F. lnterleukin-9 is expressed by primary and cultured Hodgkin and Reed-Sternberg cells. Cancer Res 1992; 52: 1026-1031.
76. Pinto A, Gloghini A, Gattei V, Aldinucci D, Zagonel V, Carbone A. Expression of the c-kit receptor in human lymphomas is restricted to Hodgkin's disease and CD30+ anaplastic large cell lymphomas. Blood 1994; 83:785-792.
77. Mertz H, Houssiau FA, Orsheschek K, Renauld JC, Fliedner A, Herin M, Noel H, Kadin M, Mueller-Hermelink HK, Van Snick J, Feller AC. Interleukin-9 expression in human malignant lymphomas: unique association with Hodgkin's disease and large cell anaplastic lymphoma. Blood 1991; 78: 1311-1317.
78. Stuart AE, Willimas AR, Habeshaw JA. Resetting and other reactions of the Reed-Sternberg cell. J Pathol 1977; 122: 81-90.
79. Sanders ME, Makgoba MW, Sussman EH, Luce GE, Cossma J, Shaw S. Molecular pathways of adhesion in spontaneous resetting of T-lymphocytes to the Hodgkin's cell line L428. Cancer Res 1988; 48: 370.
80. Delabie J, Chan WC, Weisenburger DD, De Wolf Peelers C. The antigen-presenting cell function of Reed-Sternberg cells. Leuk Lymph 1995; 18: 35-40.
81. Alzona M, Jack HM, Fisher R, Ellis TM. CD30 defines a subset of activated human T cells that produce IFN-y and IL-5 and exhibit enhanced B cell helper activity. J Immunol 1994; 153: 2861-2867.
82. Del Prête GF, De Carli M, Almerigogna F, Daniel CK, D'Elios MM, Zancuoghi G, Pizzolo G, Romagnani S. Preferential expression of CD30 by human CD4+ T-cells producing Th2type cytokines. FASEB J 1995; 9: 81-86.
83. Renauld JC, Goethals A, Haussiau F, Merz H, van Roost E, van Snick J. Human P40/IL-9. Expression in activated CD4+ T cells, genomic organization, and comparison with the mouse gene. J Immunol 1990; 144: 4235-4241.
84. Samoszuk MK, Nansen L. Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin's disease with eosinophilia. Blood 1990; 75: 13-16.
85. Samoszuk M. IgE in Reed-Sternberg cells of Hodgkin's disease with eosinophilia. Blood 1992; 76:1518-1522.
86. Mosmann TR, Sad S. The expanding universe o T-cell subsets: Thl, Th2 and more. Immunol Today 1996; 17: 138-146.
87. Gauchat JF, Henchoz S, Fattah D, Mazzei G, Aubry JP, Jomotte T, Dash L, Page K, Solan R, Aldebert D, Capron M, Dahinden C, Bonnefoy JY. CD40 ligand is functionally expressed on human eosinophils. Eur J Immunol 1995; 25: 863-865.
88. Sanderson CJ. Interleukin-5, eosinophils and disease. Blood 1992; 79: 3101-3109.
89. Wardlaw, AJ, Moqbel R, Kay AB. Eosinophils: biology and role in disease. Adv Immunol 1995; 60: 151-266.
90. Schultze J, Nadler LM, Gribben JG. B7-mediated costimulation and the immune response. Blood Rev 1996; 10:111-127.
91. Croft M, Dubey C.Accessory molecule and costimulation requirements for CD4 T cell response. Crit Rev Immunol 1997; 17:89-118.
92. Cayabyab M, Phillips JH, Lanier LL. CD40 preferentially costimulates activation of CD4+ T lymphocytes. J Immunol 1994; 152: 1523-1531.
93. Fisher RI, Bostick-Bruton F, Sauder DN, Scala G, Diehl V. Neoplastic cells obtained from Hodgkin's disease are potent stimulators of human primary mixed lymphocyte cultures. J Immunol 1983; 130: 2666-2670.
94. Fisher RI, Cossman J, Diehl V, Volkman DJ. Antigen presentation by Hodgkin's disease cells. J Immunol 1985; 135: 3568-3571.
95. Maggi E, Parronchi P, Macchia D, Bellesi G, Romagnani S. High numbers of CD4+ T cells showing abnormal recognition of DR antigens in lymphoid organs involved by Hodgkin's disease. Blood 1989; 71:1503-1506.
96. Romagnani S, Rossi Ferrini PL, Ricci M. The immune derangement in Hodgkin's disease. Sem Hematol 1985; 22: 41-55.
97. Maggi E, Parronchi P, Macchia D, Piccinni MP, Simonelli C, Romagnani S. Role of T cells in the pathogenesis of Hodgkin's disease. Int Rev Exp Pathol. 1992; 33: 141-164.
98. Schmid C, Sweeney E, Isaacson PG. Proliferating cell nuclear antigen (PCNA) expression in Hodgkin's disease. J Pathol 1992; 168: 1-6.
99. Poppema S, Visser L. Immunophenotype and functional characteristics of T cells in Hodgkin's disease. Blood 1995; 86 (Suppl. 1, 339a): 1345.
100. Fox DA, Hussey RE, Fitzgerald KA, Acuto O, Poole C, Palley L, Daley JF, Schlossman SF, Reinherz EL. Tal, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody. J Immunol 1984; 133: 1250-1256.
101. Dang NH, Torimoto Y, Schlossman SF, Morimoto C. Human CD4 helper T cell activation: functional involvement of two distinct collagen receptors, 1F7 and VLA integral family. J Exp Med 1990; 172: 649-652.
102. Fleischer B. CD26: a surface protease involved in T-cell activation. Immunol Today 1994; 15:180-184.
103. Romagnani S, Maggi E, Parronchi P, Macchia D, Del Prête GF, Rossi Ferrini PL, Ricci M, Moretta L. Clonal analysis of T lymphocytes in spleens from patients with Hodgkin's disease. Frequent occurrence of unusual T4-positive cells which coexpress cytolitic activity and production of interleukin-2. Int J Cancer 1986; 37: 343-349.
104. Poppema S, Visser L. Absence of HLA class I expression by Reed-Sternberg cells. Am J Pathol 1994; 145: 37-41.
105. Valagussa P, Santoro A, Fossati-Belloni F, Banti A, Bonadonna G. Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol 1986; 4: 830-837.
106. Tazzari PL, Bolognesi A, De Totero D, Falini B, Lemoli R, Soria M, Pileri S, Gobbi M, Stein H, Flenghi L, Martelli MF, Stupe F. Ber-H2 (anti CD30)-saporin immunotoxin: a new tool for treatment of Hodgkin's disease and CD30+ lymphoma. In vitro evaluation. Br JHaematol 1992; 81:203-211.